Final HIPAA e-transaction regs published by DHHSThe final HIPAA rules on transaction standards were published by the U.S. Department of Health and Human Services on Aug. 17, after being signed by Secretary Donna Shalala on July 26. Located at
The final HIPAA rules on transaction standards were published by the U.S. Department of Health and Human Services on Aug. 17, after being signed by Secretary Donna Shalala on July 26. Located at
http://aspe.hhs.gov/admnsimp/final/txfin00.htm
, the rules put into place national standards for eight types of electronic transactions, including claims submission, eligibility verification, referral authorizations, and coding for diagnoses. They will become effective 60 days after publication, and most healthcare organizations will have 24 months thereafter to comply. However, if privacy standards are delayed, a provision in the final transaction rules states that they can be suspended or revoked
A flurry of new product releases coincided with the DHHS publication of the final HIPAA regs, and not just by security and systems vendors. Market research firms such as the Gartner Group and First Consulting Group have also launched new tools and related products designed to help organizations comply with the HIPAA rules.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.